Form 4: Sutro Biopharma Director Jon Marc Wigginton Acquires 35,000 Stock Options
SEC Form 4 Filing
Director Jon Marc Wigginton of Sutro Biopharma, Inc. acquired 35,000 stock options on June 6, 2024, according to a recent SEC Form 4 filing.
Summary
- Jon Marc Wigginton, a director of Sutro Biopharma, Inc., acquired 35,000 stock options on June 6, 2024.
- The options have an exercise price of $3.76.
- The options vest monthly starting July 6, 2024, with full vesting by June 6, 2025, or the date of the 2025 annual stockholders meeting, whichever is earlier, contingent on continued service to the issuer.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock option grants, neither particularly positive nor negative.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, as the value of the options increases if the company's stock price increases.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Jon Marc Wigginton acquired 35,000 stock options. |
| 06/06/2024 | Date of grant: Stock options granted with an expiration date of 06/06/2034. |
| 07/06/2024 | Vesting start date: Options vest monthly, commencing on this date. |
| 06/06/2025 | Full vesting date: Options will be fully vested by this date, or the date of the issuer's 2025 annual stockholders meeting, whichever is earlier. |
| 06/10/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.